Open AccessCross-Reacting Material 197, a Specific Inhibitor of HB-EGF, and Its Anticancer Effects
Author(s) -
Maryam Tanhapour,
Abolfazl Golestani,
Asad Vaisi-Raygani,
Mahdi Aminian
Publication year - 2022
Publication title -
basic and clinical cancer research
Language(s) - English
Resource type - Journals
eISSN - 2228-6527
pISSN - 2228-5466
DOI - 10.18502/bccr.v13i1.8828
Subject(s) - diphtheria toxin , cancer research , cancer , pharmacology , epidermal growth factor , anticancer drug , apoptosis , medicine , metastasis , drug , chemistry , toxin , biochemistry , receptor
Genetic heterogeneity and metastasis remain the most challenging aspects of cancer treatment.Recent studies have introduced a mutant of diphtheria toxin,cross-reacting material197 (CRM197), as a new promising biological anticancer drug to improve cancer therapy in patients previously resistant to chemotherapy. Weak toxicity of CRM197accounts forthe stimulation ofcell apoptosis and the antitumor effect. Increasing evidence has indicated that the expression of heparin-binding epidermal growth factor-like (HB-EGF) growth factorincreases in most cancer cells, and CRM197 is its specific inhibitor.This study has focused on the structure, properties, and anticancer activity of CRM197.